Van Royen Paul

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
ACKNOWLEDGMENTS First, I would like to thank Prof. Paul Van Dooren and Prof. Vincent Blondel for the five long years as my advisors. Your support and advice have guided me through the most difficult moments of my research. Not only me, everyone will be really proud to have advisors like you. Paul and Vincent, thanks for your precious presence. for being on(More)
BACKGROUND No efficacy studies of influenza vaccination given to GPs have yet been published. Therefore, our purpose was to assess the effect of an inactivated influenza vaccine given to GPs on the rate of clinical respiratory tract infections (RTIs) and proven influenza cases (influenza positive nose and throat swabs and a 4-fold titre rise), while(More)
  • Linda Carroll-Shern, Midwest Area, Sharon D Agostino, Aventis Pharmaceuticals, Kenneth Dedeker, David Estrin +22 others
  • 2001
The recommendations contained in this report reflect positions adopted by the MMA Board of Trustees and do not, necessarily, reflect the opinions of all members of the task force. In response to four resolutions brought before the MMA House of Delegates, the MMA Board of Trustees appointed a Pharmaceutical Issues Task Force (PITF) in April 2000. In general,(More)
  • 1